These are not identical studies, so cross-trial comparison should be treated as directional rather than definitive
no consistent signal for organ toxicity or long-term harm across decades of use Special Populations: Clinical experience exists in elderly patients with dementia and stroke patients, populations where safety data is particularly valuable IV Administration Considerations: Requires clinical administration setting for intravenous dosing, which limits convenience but ensures medical oversight Dihexa: Unknown Human Safety Profile Dihexa has never been administered to humans in any controlled setting, creating a complete absence of human safety data: No Human Pharmacokinetics: Absorption, distribution, metabolism, and excretion parameters are unknown in humans Theoretical c-Met Oncogenesis Concern: The c-Met/HGF pathway is implicated in cancer progression aberrant c-Met signaling promotes tumor growth, metastasis, and angiogenesis in multiple cancer types
A., Ramos, M
It also issued other warning letters for current good manufacturing practices (CGMP) violations and failing to adhere to clinical trial protocols
Human safety data on the pure peptide is thin, drawn mostly from small older cohorts using a cruder gland extract
VitalPeptide+ Hair Solution is a targeted topical formulation featuring GHK-Cu, a copper peptide complex studied for its regenerative and hair-supportive properties
